• Some patients with advanced non-small-cell lung cancer (NSCLC) have slightly higher survival rates when treated with the chemotherapy drug cisplatin than another platinum-based drug, carboplatin, according to a study in the June 6 Journal of the National Cancer Institute . (eurekalert.org)
  • Most clinicians in North America prefer carboplatin to cisplatin because it has fewer side effects and is easier to administer. (eurekalert.org)
  • Andrea Ardizzoni, M.D., of University Hospital in Parma, Italy, and colleagues conducted a review of nine randomized trials comparing the survival of 2,968 NSCLC patients who received either cisplatin- or carboplatin-based chemotherapy. (eurekalert.org)
  • Patients who received cisplatin lived slightly longer than those treated with carboplatin, with a median survival of 9.1 months compared with 8.4 months. (eurekalert.org)
  • Carboplatin was more likely to decrease blood platelet levels, while cisplatin was more likely to cause nausea, vomiting, and damage to the kidneys. (eurekalert.org)
  • Given the palliative nature of chemotherapy treatment in advanced NSCLC and the unquestionable practical advantage of carboplatin in terms of ease of administration, it could be argued that the small benefit achieved with cisplatin relative to carboplatin does not justify its preferential use in clinical practice. (eurekalert.org)
  • In an accompanying editorial, Christopher Azzoli, M.D., and colleagues at the Memorial Sloan-Kettering Cancer Center in New York discuss the renewed rivalry between cisplatin and carboplatin, particularly in the face of new developments in adjuvant chemotherapy for NSCLC patients. (eurekalert.org)
  • The apparent superiority of cisplatin over carboplatin demonstrated in this paper should not be taken lightly, particularly in patients being treated with curative intent. (eurekalert.org)
  • Cisplatin- Versus Carboplatin-Based Chemotherapy in First-Line Treatment of Advanced Non - Small-Cell Lung Cancer: An Individual Patient Data Meta-analysis. (eurekalert.org)
  • Cisplatin Versus Carboplatin for Patients With Metastatic Non - Small-Cell Lung Cancer - An Old Rivalry Renewed. (eurekalert.org)
  • Care must be taken to avoid inadvertent cisplatin overdose due to confusion with carboplatin or prescribing practices that fail to differentiate daily doses from total dose per cycle. (nih.gov)
  • Earlier this year, the health regulator had signed off on allowing cisplatin made by China's Qilu Pharmaceutical to be sold in the U.S. The FDA had also said it was looking for additional suppliers for cancer drugs cisplatin, carboplatin and methotrexate. (yahoo.com)
  • Unlike its parent compound, Cisplatin, Carboplatin has generally caused less severe side effects in patients, causing some disagreement around cisplatin versus carboplatin. (maacenter.org)
  • Drugs used in chemotherapy, such as paclitaxel, ifosfamide, cisplatin, carboplatin, and etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. (cincinnatichildrens.org)
  • Methods: Medline was searched for 1) Cell models of acquired resistance reporting cisplatin, oxaliplatin and paclitaxel sensitivities and 2) Clinical trials of single agent oxaliplatin or paclitaxel salvage therapy for cisplatin/carboplatin-resistant ovarian cancer. (dcu.ie)
  • They include certain antibiotics like gentamicin, cancer treatment drugs like cisplatin and carboplatin, and pain relievers that contain salicylate like aspirin, quinine, loop diuretics. (cdc.gov)
  • Common neurological side effects of cisplatin include visual perception and hearing disorder, which can occur soon after treatment begins. (wikipedia.org)
  • The researchers, led by Lois B. Travis, MD, ScD , the Lawrence D. Einhorn Professor of Cancer Research at the IU School of Medicine and a researcher at the Indiana University Melvin and Bren Simon Cancer Center, studied for the first time the cumulative effects of cisplatin-based chemotherapy on hearing levels in testicular cancer survivors through comprehensive audiometry measurements. (hearingreview.com)
  • For patients treated with cisplatin-based regimens for other types of cancer, it might also influence physicians to offer an alternative to those patients found to be genetically susceptible to the ototoxic effects of cisplatin after carefully weighing the risks and benefits of alternative treatments. (hearingreview.com)
  • According to the JIB extract's anti-melanoma capacity, to assess the synergistic effects of cisplatin and JIB extract. (medsci.org)
  • Exercise caution to prevent inadvertent cisplatin overdose. (nih.gov)
  • NOTE TO THE PHARMACIST- Exercise caution to prevent inadvertent cisplatin overdosage. (globalrph.com)
  • Ototoxicity and hearing loss associated with cisplatin can be severe and is considered to be a dose-limiting side effect. (wikipedia.org)
  • Other drugs (such as the aminoglycoside antibiotic class) may also cause ototoxicity, and the administration of this class of antibiotics in patients receiving cisplatin is generally avoided. (wikipedia.org)
  • The ototoxicity of both the aminoglycosides and cisplatin may be related to their ability to bind to melanin in the stria vascularis of the inner ear or the generation of reactive oxygen species. (wikipedia.org)
  • In September 2022, the U.S. Food and Drug Administration (FDA) approved sodium thiosulfate under the brand name Pedmark to lessen the risk of ototoxicity and hearing loss in people receiving cisplatin. (wikipedia.org)
  • It is estimated that 36% of adult patients and 40% to 60% of pediatric patients experience cisplatin-induced ototoxicity. (medscape.com)
  • The risk of developing cisplatin-induced ototoxicity depends on various factors, including the cumulative dose of cisplatin, the duration of treatment, and individual patient factors, such as age and preexisting hearing problems. (medscape.com)
  • Of the 35 responding oncologists, the majority (97%) indicated that they regularly discuss the risk of ototoxicity with all patients before they receive cisplatin. (medscape.com)
  • However, only 18% of the respondents said they obtain audiograms for patients before administering cisplatin, 69% order audiograms only if patients complain of hearing loss or tinnitus, and 35% of respondents do not perform regular monitoring for ototoxicity. (medscape.com)
  • Managing cisplatin-induced ototoxicity "must be viewed as a proactive measure rather than a reactive measure," said Nisha Mohindra, MD, writing in an accompanying editorial . (medscape.com)
  • Cite this: Better Monitoring of Cisplatin-Induced Ototoxicity Needed - Medscape - Apr 28, 2023. (medscape.com)
  • The message is not that cisplatin should be avoided, but that "attention must be turned to survivorship, including an awareness of the functional impact of ototoxicity," the authors emphasize. (medscape.com)
  • Routine follow-up of adult-onset cisplatin-treated ototoxicity in cancer survivors should begin with prechemotherapy baseline measurements, resume shortly after treatment, and include annual query for hearing loss/tinnitus status and severity, especially as patients age, so that they are presented with available treatment strategies," the authors recommend. (medscape.com)
  • In the general population, HL begins in midlife, with two thirds of individuals age ≥ 70 years having bilateral HL, but for cancer survivors where treatment occurs earlier in life, cisplatin-related ototoxicity can exacerbate age-related HL," the authors explain. (medscape.com)
  • The potentially severe, negative impact of cisplatin-related ototoxicity on functional status warrants clinical intervention, survivorship support, and education," the researchers conclude. (medscape.com)
  • Subsequent cisplatin doses were decreased 50% for ototoxicity. (cancernetwork.com)
  • Because alterations to the successful testicular cancer regimens are unlikely for patients with advanced disease, the researchers point out that their results underscore the importance of ongoing research aimed at the identification of genetic variants associated with cisplatin-related ototoxicity. (hearingreview.com)
  • Our results demonstrate that Csa and Csb deficiencies predispose to cisplatin-induced hearing loss and hair/supporting cell damage in the mammalian organ of Corti, and emphasize the importance of transcription-coupled DNA repair in the protection against cisplatin ototoxicity. (eur.nl)
  • Nervous system problems may occur up to several weeks after you receive cisplatin, and these effects may not be reversible. (drugs.com)
  • How often and how many times you receive cisplatin will depend on the type of cancer you have. (drugs.com)
  • Cumulative renal toxicity associated with cisplatin is severe. (nih.gov)
  • A phase II trial associating the reference chemotherapy (pemetrexed plus cisplatin) with bevacizumab is needed to ensure that no specific toxicity is induced by this association, and that this triplet have interesting activity. (knowcancer.com)
  • It is the most ototoxic drug used clinically, and hearing loss is a well-recognized toxicity of cisplatin therapy. (cancernetwork.com)
  • The aim of the present study was to demonstrate astaxanthin's attenuating effects against cisplatin (CIS)-induced gastrointestinal toxicity in a rat model. (springermedizin.at)
  • Based on the data in this study, astaxanthin might play a protective role against cisplatin-induced gastrointestinal toxicity in rats. (springermedizin.at)
  • Zurück zum Zitat Shahid F, Farooqui Z, Khan F. Cisplatin-induced gastrointestinal toxicity: an update on possible mechanisms and on available gastroprotective strategies. (springermedizin.at)
  • Background: First-line chemotherapy for patients with cisplatin-ineligible locally advanced or metastatic urothelial carcinoma is associated with short response duration, poor survival, and high toxicity. (urotoday.com)
  • To prevent cisplatin induced kidney toxicity we used a combination of dietary plant extracts, particularly, hydro-alcoholic extract of Tribulus terrestris (TT), Boerhaavia diffusa (BD) and Terminalia chebula (TC) in rats. (scialert.net)
  • Oxaliplatin performed better in combination with other agents for the treatment of platinum-resistant cancer suggesting that the benefit of oxaliplatin may lie in its more favourable toxicity and ability to be combined with other drugs rather than an underlying activity in cisplatin resistance. (dcu.ie)
  • The aims of this study are to clarify the antitumor effects of TCEE on human hepatocellular carcinoma cells and also evaluate the combination drug effects with conventional chemotherapy agents, cisplatin and doxorubicin. (hindawi.com)
  • In combination with the chemotherapy agents, TCEE treatment further enhanced the tumor suppression efficiency of cisplatin and doxorubicin. (hindawi.com)
  • Chemotherapy agents such as doxorubicin, cisplatin, and 5-fluorouracil are the primary choices for treating liver cancer cases but the response rate and overall survival remained poor [ 3 , 4 ]. (hindawi.com)
  • Furthermore, the combined drug effects of TCEE with conventional chemotherapy agents, cisplatin and doxorubicin, were also analyzed to clarify whether TCEE enhances or antagonizes the cytotoxicity of the selected chemotherapy agents in hepatocellular carcinoma cells. (hindawi.com)
  • Scholars@Duke publication: Symptom clusters in children and adolescents receiving cisplatin, doxorubicin, or ifosfamide. (duke.edu)
  • Adjuvant or palliative treatment for adrenocortical carcinoma (AC) has been studied by using mitotane, cisplatin, etoposide, and doxorubicin. (medscape.com)
  • studies have focused on the regimen etoposide and cisplatin and on etoposide, doxorubicin, and cisplatin. (medscape.com)
  • Patients with advanced nasopharyngeal carcinoma and who were treated with gemcitabine plus cisplatin experienced a longer overall survival and improved progression-free survival vs fluorouracil plus cisplatin. (cancernetwork.com)
  • Patients with recurrent or metastatic nasopharyngeal carcinoma who received first-line gemcitabine plus cisplatin had longer overall survival (OS) compared with fluorouracil plus cisplatin, according to the results of the phase 3 GEM20110714 study (NCT01528618) published in the Journal of Clinical Oncology . (cancernetwork.com)
  • Investigators determined that gemcitabine plus cisplatin yielded a median OS of 22.1 months (95% CI, 19.2-25.0) compared with 18.6 months (95% CI, 15.4-21.7) for fluorouracil plus cisplatin. (cancernetwork.com)
  • The probability of OS was 79.9 at 1 year %, 31.0% at 3 years, and 19.2% at 5 years for gemcitabine plus cisplatin and at 71.8% at 1 year, 20.4% at 3 years, and 7.8% at 5 years for fluorouracil plus cisplatin. (cancernetwork.com)
  • The GEM20110714 study established the role of first-line [gemcitabine plus cisplatin] for patients with [recurrent or metastatic nasopharyngeal carcinoma]. (cancernetwork.com)
  • The results show that the [gemcitabine plus cisplatin] regimen produces an OS benefit for these patients, with a 28% reduction in the risk of death and an improvement of almost 4 months in median OS," the study's investigators wrote. (cancernetwork.com)
  • A total of 362 patients were enrolled on the trial and were randomized 1:1 to receive either gemcitabine plus cisplatin (n = 181) or the fluorouracil plus cisplatin (n = 181). (cancernetwork.com)
  • In December of 2020, the duration of follow-up was comparable between the 2 cohorts, including 69.5 months (95% CI, 63.3-75.6) with gemcitabine plus cisplatin and 69.7 months (95% CI, 56.4-83.0) for fluorouracil plus cisplatin. (cancernetwork.com)
  • Of this population, 86.7% died (n = 314), including 81.8% (n = 148) of the gemcitabine plus cisplatin arm and 91.7% (n = 166) of the fluorouracil plus cisplatin arm. (cancernetwork.com)
  • The restricted mean value time for OS was 33.0 months (95% CI, 29.3-37.2) in the gemcitabine plus cisplatin group and 25.4 months (95% CI, 22.4-28.6) in the fluorouracil plus cisplatin group ( P = .003). (cancernetwork.com)
  • After discontinuing treatment, 51.9% (n = 94) of patients in the gemcitabine plus cisplatin group and 55.2% (n = 100) of patients in the fluorouracil plus cisplatin group started a first subsequent systemic therapy. (cancernetwork.com)
  • Within this population, 68.1% (n = 64) and 83.0% (n = 83) received a platinum-based combination therapy in both the gemcitabine plus cisplatin and fluorouracil plus cisplatin groups, respectively. (cancernetwork.com)
  • Additionally, a second subsequent therapy was administered to 37.2% (n = 35) of patients in the gemcitabine plus cisplatin arm and 47.0% (n = 47) of patients in the fluorouracil plus cisplatin arm. (cancernetwork.com)
  • The purpose of this study is to assess the antitumor effectiveness and safety of perioperative enfortumab vedotin (EV) plus pembrolizumab and radical cystectomy (RC) + pelvic lymph node dissection (PLND) compared with the current standard of care (neoadjuvant chemotherapy [gemcitabine plus cisplatin] and RC + PLND) for participants with MIBC who are cisplatin-eligible. (mayo.edu)
  • Plasma concentrations of the parent compound, cisplatin, decay monoexponentially with a half-life of about 20 to 30 minutes following bolus administrations of 50 or 100 mg/m 2 doses. (nih.gov)
  • Many testicular cancer survivors experience hearing loss after cisplatin-based chemotherapy , according to researchers at Indiana University , who found that increasing doses of cisplatin were associated with increased hearing loss. (hearingreview.com)
  • They found that increased doses of cisplatin were associated with increased hearing loss at most of the tested frequencies, involving 4, 6, 8, 10, and 12 kHz. (hearingreview.com)
  • Animals (n = 6 per group) were randomly assigned into six groups: A normal control, cisplatin control, the drug-combination armat doses of 198, 300 and 600 mg kg 1 of equal ratio of each of TT, BD and TC and the combination of 300 mg kg 1 per se group. (scialert.net)
  • In a phase Ib/II study reported in the Journal of Clinical Oncology , Christopher J. Hoimes, MD , and colleagues found that first-line enfortumab vedotin-ejfv plus pembrolizumab produced a high response rate and prolonged response durations in cisplatin-ineligible, previously untreated patients with advanced urothelial cancer. (ascopost.com)
  • You may have a severe allergic reaction within minutes of receiving a cisplatin injection. (drugs.com)
  • Cisplatin Injection should be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents. (nih.gov)
  • Cisplatin Injection infusion concentrate is a clear, colorless, sterile aqueous solution. (nih.gov)
  • Each 50 mL or 100 mL amber vial of Cisplatin Injection contains: 1 mg/mL cisplatin, 9 mg/mL sodium chloride, hydrochloric acid and/or sodium hydroxide to adjust pH, and water for injection to a final volume of 50 mL or 100 mL, respectively. (nih.gov)
  • The pH range of Cisplatin Injection is 3.8 to 5.9. (nih.gov)
  • This leaflet answers some common questions about DBL Cisplatin Injection. (news-medical.net)
  • DBL Cisplatin Injection belongs to a group of medicines known as antineoplastic or cytotoxic agents. (news-medical.net)
  • DBL Cisplatin Injection is a platinum-containing medicine and is used as an anticancer drug to interfere with the growth of cancer cells and eventually destroy them. (news-medical.net)
  • DBL Cisplatin Injection may be used alone or with other anticancer therapies. (news-medical.net)
  • DBL Cisplatin Injection has been chosen as your therapy, as the benefits of treatment are expected to be greater than the unwanted or side effects. (news-medical.net)
  • The active ingredient in DBL Cisplatin Injection passes into breast milk and there is a possibility that your baby may be affected. (news-medical.net)
  • Do not dilute cisplatin in just 5% Dextrose Injection. (globalrph.com)
  • Cisplatin Injection is a sterile, multidose vial without preservatives. (globalrph.com)
  • Cisplatin is mainly used in treatment of non-small cell lung carcinoma, in combination with gemcitabine, paclitaxel, docetaxel, etoposide or vinorelbine [ 9 ]. (ijpsonline.com)
  • Stordal, Britta , Pavlakis, Nick and Davey, Ross (2009) Treating cisplatin-resistant cancer: a systematic analysis of oxaliplatin or paclitaxel salvage chemotherapy. (dcu.ie)
  • Objective: To examine the pre-clinical and clinical evidence for the use of oxaliplatin or paclitaxel salvage chemotherapy in patients with cisplatin-resistant cancer. (dcu.ie)
  • Paclitaxel - Cellular data suggests that paclitaxel is active in cisplatin-resistant cancer. (dcu.ie)
  • 68.1% of cisplatin-resistant cells were sensitive to paclitaxel. (dcu.ie)
  • Paclitaxel-resistant cells were also sensitive to cisplatin, suggesting that alternating between agents may be beneficial. (dcu.ie)
  • Conclusions: Cellular models reflect the resistance observed in the clinic as the cross resistant agent oxaliplatin has a lower response rate compared to the non-cross resistant agent paclitaxel in cisplatin-resistant ovarian cancer. (dcu.ie)
  • Alternating therapy with cisplatin and paclitaxel may therefore lead to an improved response rate in ovarian cancer. (dcu.ie)
  • Effects of specific anti-miRs for the five miRNAss on the IC50 of cisplatin (A) and paclitaxel (B) in Hec1A cells. (figshare.com)
  • Hemolytic anemia can be developed after several courses of cisplatin. (wikipedia.org)
  • The present study was undertaken to examine the mechanistic basis for the recent observation that the pyridine nucleotide derivative 6-aminonicotinamide (6AN, NSC 21206) enhances the accumulation and resulting cytotoxicity of cisplatin in a variety of tumor cell lines. (aspetjournals.org)
  • Cisplatin is used together with other cancer drugs to treat bladder cancer , testicular cancer , or ovarian cancer . (drugs.com)
  • In this video, Shilpa Gupta, MD, discusses the background and findings of the study, "Results from BLASST-1 (Bladder Cancer Signal Seeking Trial) of nivolumab, gemcitabine, and cisplatin in muscle invasive bladder cancer (MIBC) undergoing cystectomy," which was presented at the 2022 ASCO Genitourinary Cancers Symposium. (urologytimes.com)
  • Prof Matt D Galsky speaks to ecancer at ASCO GU 2023 about his talk on the co-primary endpoint analysis of HCRN GU 16-257, a phase 2 trial of gemcitabine, cisplatin, plus nivolumab with selective bladder sparing in patients with muscle-invasive bladder cancer. (ecancer.org)
  • Prof Galsky concludes the results show transurethral resection of the bladder tumour followed by gemcitabine, cisplatin, plus nivolumab achieves a stringently defined clinical complete response in a substantial subset of patients with muscle-invasive bladder cancer. (ecancer.org)
  • Cisplatin is administered intravenously as short-term infusion in normal saline for treatment of solid and haematological malignancies. (wikipedia.org)
  • It is recommended that you and your doctor discuss your need for cisplatin treatment during pregnancy and the possible risks and benefits of using cisplatin during pregnancy. (news-medical.net)
  • Avoid becoming pregnant by using effective birth control during your treatment with cisplatin and for at least 26 weeks after you stop treatment (at least 31 weeks if have kidney disease). (news-medical.net)
  • Males: Tell your doctor or pharmacist if your partner intends to become pregnant while you are being given cisplatin, or shortly after you have stopped treatment. (news-medical.net)
  • It is recommended that you use effective contraception while you are using cisplatin and for at least 14 weeks after you stop treatment (at least 19 weeks if you have kidney disease). (news-medical.net)
  • However, because treatment involves cisplatin-based chemotherapy, these TC survivors are at risk for both short- and long-term adverse CBCT-related effects, including HL and tinnitus, with no preventive or protective measures available. (medscape.com)
  • Mutations potentially acquired during cisplatin treatment included NF1 missense mutations of uncertain significance in two patients and a KIT G565R activating mutation in one patient. (nih.gov)
  • We found that cisplatin treatment can potentially double the mutational burden in osteosarcoma, which has implications for optimizing therapy for recurrent, chemotherapy-resistant disease. (nih.gov)
  • The reported incidence of hearing loss varies with differences in treatment protocols and patient variables, but hearing loss generally occurs in 20% to 70% of cisplatin recipients. (cancernetwork.com)
  • DK completed treatment in October 2001 after receiving a cumulative cisplatin dose of 450 mg/m2. (cancernetwork.com)
  • In the present study, an attempt was made to achieve better treatment of lung cancer by direct lung delivery of cisplatin microparticulate systems, which helps to localize the drug in the lungs, and also provide sustained action. (ijpsonline.com)
  • In this study, we demonstrated that NSCLC-derived CAFs were innately resistant to cisplatin treatment and CAFs-conditioned medium significantly promoted the survival rate of NSCLC cells after cisplatin treatment. (dovepress.com)
  • Recently, combination chemotherapy with cisplatin (CDDP) becomes one of effective treatment against gastric cancer, clinically. (aacrjournals.org)
  • and unlike Xpc−/− mice, Csa−/− and Csb−/− mice lose hearing and manifest outer hair cell degeneration after systemic cisplatin treatment. (eur.nl)
  • foot note: # anti-miR200b* slightly decreased total cell count with marginal significance in cisplatin treatment. (figshare.com)
  • According to the results from the phase III JUPITER-02 study, the addition of toripalimab, a humanized IgG4K anti- PD-1 monoclonal antibody , to standard gemcitabine/cisplatin chemotherapy as first-line treatment for patients with advanced nasopharyngeal carcinoma provided superior progression-free survival and objective response, as well as a longer duration of response, compared with combination chemotherapy alone. (ascopost.com)
  • Currently, the standard of care in the first-line treatment setting for locally advanced, recurrent, or metastatic nasopharyngeal carcinoma is combination gemcitabine/cisplatin chemotherapy. (ascopost.com)
  • The addition of toripalimab to gemcitabine/cisplatin chemotherapy as first-line treatment for patients with advanced nasopharyngeal carcinoma provided superior progression-free survival compared with chemotherapy and placebo, with a median of 11.7 months vs 8 months, respectively. (ascopost.com)
  • The addition of toripalimab to gemcitabine/cisplatin chemotherapy as first-line treatment for patients with advanced nasopharyngeal carcinoma provided superior progression-free survival and objective response rate and longer duration of response than gemcitabine/cisplatin alone with a manageable safety profile. (ascopost.com)
  • On the contrary, treatment with the protein synthesis inhibitors cycloheximide, anisomycin, or puromycin as well as prolonged exposure to the RNA synthesis inhibitor actinomycin D mimicked the biochemical modulating effects of 6AN on cisplatin action. (aspetjournals.org)
  • In the treatment of unresectable advanced HCC, cisplatin is administered transhepatic arterially for local treatment . (bvsalud.org)
  • Cisplatin is also used for the treatment of liver tumors other than HCC. (bvsalud.org)
  • This review summarizes the action and resistance mechanism of cisplatin and describes the treatment of the major hepatobiliary cancers for which cisplatin is used as an anticancer agent , with a focus on HCC. (bvsalud.org)
  • KEMPINAS, W. G. Paternal treatment with cisplatin impairs reproduction of adult male offspring in rats. (bvsalud.org)
  • Oxaliplatin as a single agent had a poor response rate in patients with cisplatin-resistant ovarian cancer (8%, n=91). (dcu.ie)
  • The dual primary hypotheses are preoperative EV + pembrolizumab and RC + PLND (Arm A) will achieve superior pathologic complete response (pCR) rate and perioperative EV and pembrolizumab and RC + PLND (Arm A) will achieve superior event free survival (EFS) compared with neoadjuvant gemcitabine + cisplatin and RC + PLND (Arm B). (mayo.edu)
  • Enfortumab vedotin and pembrolizumab have shown a survival benefit vs chemotherapy in urothelial cancer, are not restricted by cisplatin eligibility, and warrant investigation as a first-line combination therapy in patients ineligible for cisplatin. (ascopost.com)
  • This phase Ib/II trial finds the best dose of selinexor and its effect with pembrolizumab in treating patients with urothelial carcinoma that are not eligible to receive the chemotherapy drug cisplatin, or have been given cisplatin and the cancer has gotten worse. (bcan.org)
  • I. To determine the recommended phase 2 dose (RP2D) of selinexor in combination with standard-dose pembrolizumab in patients with advanced urothelial carcinoma who are cisplatin-ineligible or platinum-refractory. (bcan.org)
  • To determine the objective response rate (ORR) of selinexor in combination with pembrolizumab in patients with advanced urothelial carcinoma who are cisplatin-ineligible or platinum-refractory. (bcan.org)
  • Your doctor has weighed the risks of you being given cisplatin against the benefits they expect it will have for you. (news-medical.net)
  • They indicate that it will be important to follow patients given cisplatin-based chemotherapy long-term to better understand the extent to which the natural aging process may further add to hearing deficits, as it does in the general population. (hearingreview.com)
  • p53 mutation and cyclin D1 amplification correlate with cisplatin sensitivity in xenografted human squamous cell carcinomas from head and neck. (lu.se)
  • Your doctor should discuss this issue with you before you begin therapy with cisplatin. (news-medical.net)
  • In the present study, chitosan-loaded cisplatin microspheres were prepared and evaluated for dry powder inhalation delivery of cisplatin for local action of the drug in lungs, and thereby achieve improved therapy in lung cancer. (ijpsonline.com)
  • Most often, Alimta is used in combination with cisplatin as a first-line therapy after a clinical trial showed pemetrexed plus Cisplatin extended the patients' survival to about 12 months, compared to 9 months when treated with cisplatin on its own. (maacenter.org)
  • This "triplet" therapy showed promising results, with patients' experiencing a median survival of 19 months versus 16 months with the combination of just Alimta and Cisplatin. (maacenter.org)
  • Patients in the fluorouracil plus cisplatin arm who received a first subsequent therapy had a partial response of 17.0%, 52.0% had stable disease, and 20% developed progressive disease. (cancernetwork.com)
  • Cisplatin in cancer therapy: molecular mechanisms of action. (springermedizin.at)
  • Collectively, our results indicate that JIB extract showed anti-tumor effects and synergized with cisplatin against B16/F10 cells, indicating the possibility of JIB extract to be developed as adjuvant therapy for melanoma. (medsci.org)
  • Cisplatin in Liver Cancer Therapy. (bvsalud.org)
  • Subsequently, for cisplatin -refractory cases due to drug resistance , a shift to systemic therapy with a different mechanism of action is expected to produce new antitumor effects. (bvsalud.org)
  • Cisplatin has a number of side effects that can limit its use: Nephrotoxicity (kidney damage) is the primary dose-limiting side effect and is of major clinical concern. (wikipedia.org)
  • A child treated with cisplatin may need a hearing test before receiving the first dose. (drugs.com)
  • Pretreatment hydration with 1 to 2 liters of fluid infused for 8 to 12 hours prior to a cisplatin dose is recommended. (globalrph.com)
  • Despite its use for more than 40 years, knowledge about the effects of cumulative cisplatin dose on hearing loss in survivors of adult-onset cancer has been limited. (hearingreview.com)
  • The IU researchers found that every 100 mg/m2 increase in cumulative dose of cisplatin resulted in a 3.2 dB impairment in hearing. (hearingreview.com)
  • The researchers also found high blood pressure was significantly related to hearing loss in these patients, even when cisplatin dose was taken into account. (hearingreview.com)
  • Nephrotoxicity was induced by single dose of cisplatin 8 mg kg 1 , i.p on the 7th day. (scialert.net)
  • Regimens of radiotherapy and chemotherapy that contain cisplatin improve the rates of survival and progression-free survival among women with locally advanced cervical cancer. (nih.gov)
  • This is a case report of a 77-year-old Spanish male patient with localized SCC of the colon, who presented a pathological complete response in the surgical specimen after neoadjuvant chemotherapy with cisplatin and etoposide. (mdpi.com)
  • Cisplatin shows its anticancer activity by coordinating to DNA where it inhibits both replication and transcription, and induces programmed cell death [ 10 ]. (ijpsonline.com)
  • Another clinical trial conducted between 2008 and 2014, found a median survival of 16 months for 225 patients treated with a combination of pemetrexed + Cisplatin. (maacenter.org)
  • The median duration of response and median overall survival exceeding 2 years in a cisplatin-ineligible patient population make this a promising combination currently under investigation in a phase III study ( ClinicalTrials.gov identifier NCT04223856 ). (ascopost.com)
  • The results demonstrated that JIB extract combined with cisplatin enhanced the inhibition of cell growth, proliferation, and survival through the obstruction of cell cycle progression and AKT/mTOR and MAPK signaling as well as the induction of cell apoptosis. (medsci.org)
  • Cisplatin showed concentration-dependent antitumor effects due to loss of cell adhesion and spheroid disruption in each cell line, while cetuximab exhibited antitumor effects that correlated with EGFR expression in each cell line. (medsci.org)
  • For their study, Sanchez and colleagues enrolled cisplatin-treated testicular cancer survivors at eight cancer centers between 2012 and 2018. (medscape.com)
  • Cisplatin is one of the most commonly used chemotherapeutic agents for treating a variety of cancers, such as lung, bladder, and ovarian cancers. (medscape.com)
  • Cisplatin (cis-diamminedichloroplatinum II, CDDP) is a chemotherapeutic agent that induces nephrotoxicity associated with oxidative/nitrosative stress. (weeksmd.com)
  • Cisplatin is a common and effective chemotherapeutic agent, yet it often causes permanent hearing loss as a result of sensory hair cell death. (eur.nl)
  • One of the first-line chemotherapeutic agents, cisplatin (also known as DDP), has been universally found to benefit individuals with advanced, unresectable or metastatic GBC [ 5 , 6 ]. (oncotarget.com)
  • Taken together, these results suggest that CAFs-derived exosomes confer cisplatin resistance of NSCLC cells through transferring miRNA-130a and that PUM2 is a critical factor for packaging miRNA-130a into exosomes. (dovepress.com)
  • This study indicates that CAFs-derived exosomal miRNA-130a may be a potential therapeutic target for cisplatin resistance in NSCLC. (dovepress.com)
  • 9 , 10 As such, it is urgent to improve the efficacy of chemotherapy to NSCLC and explore the molecular mechanism underlying cisplatin resistance of NSCLC. (dovepress.com)
  • Radiation will overcome acquired chemo-resistance with cisplatin in gastric cancer cell. (aacrjournals.org)
  • Objective This study aimed to evaluate the effects of CIK cells on cisplatin (DDP) resistance in the human lung adenocarcinoma cell line A549/DDP. (jcancer.org)
  • Our results demonstrated that miR-31reduced significantly in GBC cells rendering resistance to cisplatin, and upregulated expression of miR-31 augmented chemosensitivity, presenting a therapeutic potential to overcome drug resistance in GBC. (oncotarget.com)
  • While triggering apoptosis through interfering with DNA replication remains the primary mechanism of cisplatin, this has not been found to contribute to neurological side effects. (wikipedia.org)
  • Methods: For this single-arm, multicentre, phase 2 study, in 47 academic medical centres and community oncology practices in seven countries in North America and Europe, we recruited previously untreated patients with locally advanced or metastatic urothelial cancer who were cisplatin ineligible. (urotoday.com)
  • More than half of adult and pediatric patients with cancer treated with cisplatin developed hearing impairment with major impact on patients' health-related quality of life," researchers note in a clinical review that was published in JCO Oncology Practice in March. (medscape.com)
  • More than half of patients with testicular cancer treated with first-line cisplatin-based chemotherapy in a recent study developed hearing loss (HL) or tinnitus. (medscape.com)
  • Reuters) - The U.S. Food and Drug Administration (FDA) said on Monday that Accord Healthcare has resumed manufacturing of commonly used cancer drug cisplatin against the backdrop of ongoing drug shortages in the United States. (yahoo.com)
  • Cisplatin is a type of chemotherapy drug used alone or in combination with other drugs to treat several advanced forms of cancer, including bladder, ovarian and testicular cancer. (yahoo.com)
  • Although this study was conducted in patients with testicular cancer, the authors point out that the general conclusions are likely applicable to patients with other types of adult-onset cancers that are commonly treated with cisplatin. (hearingreview.com)
  • In 1974, Dr. Einhorn tested cisplatin with two additional drugs that were effective in killing testis cancer cells. (hearingreview.com)
  • For this study of cisplatin-related hearing loss, which was also covered by Sanjay Gupta, MD, in his " The Gupta Guide" column, the researchers studied 488 men enrolled in the Platinum Study, which is open at the IU Simon Cancer Center and 7 other cancer centers in the United States and Canada. (hearingreview.com)
  • Cisplatin is a potent anti-cancer agent, however, its usage is limited due to its nephrotoxicity. (scialert.net)
  • Results: Oxaliplatin - Oxaliplatin is widely regarded as being active in cisplatin-resistant cancer. (dcu.ie)
  • Oxaliplatin therefore should not be considered broadly active in cisplatin-resistant cancer. (dcu.ie)
  • Ravinayagam, V. Synergistic action of curcumin and cisplatin on spinel ferrite/hierarchical MCM-41 nanocomposite against MCF-7, HeLa and HCT 116 cancer cell line. (beilstein-journals.org)
  • Cisplatin interferes with DNA replication, which kills the fastest proliferating cells, which in theory are cancerous. (wikipedia.org)
  • Cisplatin impairs fluid and electrolyte absorption in rat small intestine: a role for 5‑hydroxytryptamine. (springermedizin.at)
  • The cisplatin remaining in the amber vial following initial entry is stable for 28 days protected from light or for 7 days under fluorescent room light. (globalrph.com)
  • Is cisplatin-ineligible, as defined by meeting any one of the cisplatin ineligibility criteria as per protocol. (mayo.edu)
  • In the control arm, patients were treated with 4 g/m2 of continuous intravenous fluorouracil starting from day 1 and 80 mg/m2 of cisplatin on day 1. (cancernetwork.com)
  • Nausea and vomiting: cisplatin is one of the most emetogenic chemotherapy agents, but this symptom is managed with prophylactic antiemetics (ondansetron, granisetron, etc.) in combination with corticosteroids. (wikipedia.org)
  • The findings-presented by Xu et al during the 2021 ASCO Annual Meeting ( Abstract LBA2 )-support the use of toripalimab with gemcitabine/cisplatin as the new standard of care for this patient population, according to the study authors. (ascopost.com)
  • Nucleotide excision repair (NER) is a conserved and versatile DNA repair pathway for many DNA-distorting lesions, including cisplatin-DNA adducts. (eur.nl)
  • Conversely, 6AN inhibited protein synthesis, whereas 18 6AN analogs that failed to enhance Pt-DNA adducts and cisplatin cytotoxicity failed to inhibit protein synthesis. (aspetjournals.org)
  • These observations are consistent with a model in which 6AN and other inhibitors of protein synthesis act as modulating agents by increasing cisplatin accumulation, thereby enhancing the formation of Pt-DNA adducts and subsequent cisplatin-induced cell death. (aspetjournals.org)
  • The cultures were exposed to cisplatin and cetuximab and the morphological changes of spheroids over time and the expression changes of target proteins were compared. (medsci.org)
  • Our results suggest that the combination of TT, BD and TC may be efficacious in attenuating cisplatin-induced nephrotoxicity by decreasing the renal level of platinum, reactive oxygen species (ROS) and oxidative stress. (scialert.net)
  • Sulforaphane protects against cisplatin-induced nephrotoxicity. (weeksmd.com)
  • INT230-6 is composed of cisplatin, vinblastine, and an amphiphilic cell-penetration excipient small molecule that improves intracellular transport and tissue dispersion by passive diffusion," said Dr Thomas. (ahdbonline.com)
  • In a clinical trial held from 2008 to 2014, 223 patients received a combination of Avastin, Alimta and Cisplatin. (maacenter.org)
  • Equally inadvisable would be the overzealous use of cisplatin in patients with metastatic NSCLC for whom the drug may be poorly tolerated, such as those with significant baseline renal impairment, hearing loss, peripheral neuropathy, or other serious medical comorbidities," the authors write. (eurekalert.org)
  • Recent studies have shown that cisplatin noncompetitively inhibits an archetypal, membrane-bound mechanosensitive sodium-hydrogen ion transporter known as NHE-1. (wikipedia.org)
  • Cisplatin, a platinum compound, exerts its cytotoxic effects by coordinating to DNA where it inhibits both replication and transcription, and induces programmed cell death. (ijpsonline.com)
  • Cisplatin inhibits DNA synthesis and, therefore, cell proliferation, by causing DNA cross-linking and denaturation of the double helix. (medscape.com)
  • Electrolyte disturbance: Cisplatin can cause hypomagnesaemia, hypokalaemia and hypocalcaemia. (wikipedia.org)